$SONN
Sonnet Biotherapeutics Holdings Inc Stock $sonn

$sonn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016046 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$36.85K	$36.45K	$95.32K
YoY Change	-40.63%	-61.77%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.543M	$1.885M	$1.900M
YoY Change	-32.35%	-0.83%	-13.62%
% of Gross Profit
Research & Development	$2.409M	$3.817M	$6.405M
YoY Change	-57.35%	-40.41%	66.8%
% of Gross Profit
Depreciation & Amortization	$3.210K	$3.210K	$3.210K
YoY Change	0.0%	0.0%	-67.9%
% of Gross Profit
Operating Expenses	$3.952M	$5.701M	$8.306M
YoY Change	-50.16%	-31.36%	37.51%
Operating Profit	-$3.915M	-$5.665M	-$8.210M
YoY Change	-50.23%	-31.0%
Interest Expense	-$31.43K	-$2.300K	$1.720K
YoY Change	221.04%	-233.72%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$3.947M	-$5.667M	-$8.209M
YoY Change	-49.9%	-30.96%	35.9%
Income Tax
% Of Pretax Income
Net Earnings	-$3.947M	-$5.667M	-$8.208M
YoY Change	-49.9%	-30.96%	35.92%
Net Earnings / Revenue	-10710.29%	-15549.65%	-8611.52%
Basic Earnings Per Share	-$0.13	-$0.34	-$1.91
Diluted Earnings Per Share	-$0.13	-$0.34	-$136.1K
COMMON SHARES
Basic Shares Outstanding	27.48M shares	20.23M shares	4.307M shares
Diluted Shares Outstanding	29.38M shares	750.6K shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.021M	$11.39M	$13.64M
YoY Change	34.38%	-16.47%	102.31%
Cash & Equivalents	$7.021M	$11.39M	$13.64M
Short-Term Investments
Other Short-Term Assets	$1.863M	$1.209M	$1.280M
YoY Change	-4.2%	-5.58%	93.96%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$9.633M	$13.05M	$14.92M
YoY Change	34.37%	-12.54%	101.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$36.58K	$39.79K	$130.6K
YoY Change	-25.99%	-69.54%	-43.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$155.4K	$0.00
YoY Change
Total Long-Term Assets	$401.9K	$265.5K	$130.6K
YoY Change	25.3%	103.23%	-43.2%
TOTAL ASSETS
Total Short-Term Assets	$9.633M	$13.05M	$14.92M
Total Long-Term Assets	$401.9K	$265.5K	$130.6K
Total Assets	$10.03M	$13.31M	$15.05M
YoY Change	33.98%	-11.53%	97.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.024M	$4.500M	$4.036M
YoY Change	0.16%	11.49%	111.33%
Accrued Expenses	$3.315M	$3.112M	$2.185M
YoY Change	3.47%	42.47%	-26.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$750.00	$750.00
YoY Change	-100.0%	0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.466M	$7.774M	$6.513M
YoY Change	-0.59%	19.36%	20.61%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$150.2K	$168.9K	$0.00
YoY Change	-31.93%		-100.0%
Total Long-Term Liabilities	$150.2K	$168.9K	$0.00
YoY Change	-31.93%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.466M	$7.774M	$6.513M
Total Long-Term Liabilities	$150.2K	$168.9K	$0.00
Total Liabilities	$6.616M	$7.943M	$6.513M
YoY Change	-1.62%	21.95%	16.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$106.6M	-$102.6M
YoY Change	26.9%
Common Stock	$3.839K	$2.050K
YoY Change	-36.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.418M	$5.369M	$8.533M
YoY Change
Total Liabilities & Shareholders Equity	$10.03M	$13.31M	$15.05M
YoY Change	33.98%	-11.53%	97.2%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.947M	-$5.667M	-$8.208M
YoY Change	-49.9%	-30.96%	35.92%
Depreciation, Depletion And Amortization	$3.210K	$3.210K	$3.210K
YoY Change	0.0%	0.0%	-67.9%
Cash From Operating Activities	-$6.172M	-$4.696M	-$5.609M
YoY Change	-21.12%	-16.28%	-3.13%
INVESTING ACTIVITIES
Capital Expenditures	$12.00K	$261.2K	-$165.6K
YoY Change	-102.05%	-257.73%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$12.00K	-$261.2K	-$165.6K
YoY Change	-97.95%	57.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.815M	14.65M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-6.172M	-4.696M	-5.609M
Cash From Investing Activities	-12.00K	-261.2K	-165.6K
Cash From Financing Activities	1.815M	14.65M	0.000
Net Change In Cash	-4.369M	9.690M	-5.774M
YoY Change	-48.05%	-267.81%	-231.53%
FREE CASH FLOW
Cash From Operating Activities	-$6.172M	-$4.696M	-$5.609M
Capital Expenditures	$12.00K	$261.2K	-$165.6K
Free Cash Flow	-$6.184M	-$4.957M	-$5.443M
YoY Change	-14.57%	-8.93%	-5.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001106838
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	SONN	Stock Issued During Period Value Net Share Settlement Of Warrants StockIssuedDuringPeriodValueNetShareSettlementOfWarrants		usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q1	us-gaap	Notes Payable Current Related And Nonrelated Party Status Extensible Enumeration NotesPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q3	us-gaap	Notes Payable Current Related And Nonrelated Party Status Extensible Enumeration NotesPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1	SONN	Stock Issued During Period Value Net Share Settlement Of Warrants StockIssuedDuringPeriodValueNetShareSettlementOfWarrants		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
	SONN	Increase Decrease In Incentive Tax Receivable IncreaseDecreaseInIncentiveTaxReceivable		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	SONN	Net Settlement Of Warrants NetSettlementOfWarrants		usd
	SONN	Inprocess Research And Development In Accounts Payable InprocessResearchAndDevelopmentInAccountsPayable		usd
	SONN	Deferred Offering Costs Charged Against Proceeds From Sale Of Common Stock DeferredOfferingCostsChargedAgainstProceedsFromSaleOfCommonStock		usd
	SONN	Issuance Of Common Stock On Vesting Of Restricted Stock Units IssuanceOfCommonStockOnVestingOfRestrictedStockUnits		usd
	SONN	Common Stock Issuance Costs In Accounts Payable CommonStockIssuanceCostsInAccountsPayable		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35570
	dei	Entity Registrant Name EntityRegistrantName	SONNET BIOTHERAPEUTICS HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2932652
	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Overlook Center
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 102
	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
	dei	City Area Code CityAreaCode	(609)
	dei	Local Phone Number LocalPhoneNumber	375-2227
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	SONN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27478686	shares
CY2023Q1	us-gaap	Cash Cash	11390177	usd
CY2022Q3	us-gaap	Cash Cash	3052879	usd
CY2023Q1	SONN	Incentive Tax Receivable Current IncentiveTaxReceivableCurrent	447010	usd
CY2022Q3	SONN	Incentive Tax Receivable Current IncentiveTaxReceivableCurrent	717305	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1208641	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1643743	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	13045828	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	5413927	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39789	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46211	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	225709	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	256594	usd
CY2022Q3	us-gaap	Deferred Costs DeferredCosts	113280	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	748	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4500043	usd
CY2023Q1	us-gaap	Assets Assets	13311326	usd
CY2022Q3	us-gaap	Assets Assets	5830012	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	748	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4752340	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3112282	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3193972	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67920	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	51328	usd
CY2023Q1	us-gaap	Deferred Income Current DeferredIncomeCurrent	92731	usd
CY2022Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	166431	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7773724	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8164819	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	168939	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	203912	usd
CY2023Q1	us-gaap	Liabilities Liabilities	7942663	usd
CY2022Q3	us-gaap	Liabilities Liabilities	8368731	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20498370	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20498370	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5544528	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5544528	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	2050	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	554	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	107986885	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88871786	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-102620272	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91411059	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5368663	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2538719	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13311326	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5830012	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36445	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	95320	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73700	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	225119	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3816644	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6405273	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7562584	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10671138	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1884569	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1900263	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3788278	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3979149	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	5701213	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	8305536	usd
	us-gaap	Operating Expenses OperatingExpenses	11350862	usd
	us-gaap	Operating Expenses OperatingExpenses	14650287	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5664768	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8210216	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11277162	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14425168	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2303	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1717	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	67949	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	15688	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5667071	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8208499	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11209213	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14409480	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.35
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16514377	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4306775	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11664815	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4306709	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2538719	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4452012	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	91617	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-5542142	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3537232	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14515968	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56998	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5667071	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5368663	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	22259847	usd
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	332075	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-6200981	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16390941	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	350891	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8208499	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	8533333	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11209213	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14409480	usd
	us-gaap	Depreciation Depreciation	6422	usd
	us-gaap	Depreciation Depreciation	6422	usd
	SONN	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	112000	usd
	SONN	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	285627	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	30885	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	45213	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	148615	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	682966	usd
	SONN	Increase Decrease In Incentive Tax Receivable IncreaseDecreaseInIncentiveTaxReceivable	-270295	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-435102	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	90659	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-386979	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	255121	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	74250	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-205474	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-18381	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-45529	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-73700	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-225119	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10610704	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13700912	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	261250	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	285627	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-261250	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-285627	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	19209252	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19209252	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8337298	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13986539	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3052879	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27622067	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11390177	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13635528	usd
	SONN	Net Settlement Of Warrants NetSettlementOfWarrants	23	usd
	SONN	Inprocess Research And Development In Accounts Payable InprocessResearchAndDevelopmentInAccountsPayable	12000	usd
	SONN	Deferred Offering Costs Charged Against Proceeds From Sale Of Common Stock DeferredOfferingCostsChargedAgainstProceedsFromSaleOfCommonStock	32340	usd
	SONN	Issuance Of Common Stock On Vesting Of Restricted Stock Units IssuanceOfCommonStockOnVestingOfRestrictedStockUnits	5	usd
	SONN	Common Stock Issuance Costs In Accounts Payable CommonStockIssuanceCostsInAccountsPayable	208932	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_z94GRF8iiDA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_821_zXp406V6nvI">Organization and Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Description of business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonnet BioTherapeutics, Inc. (“Prior Sonnet”) was incorporated as a New Jersey corporation on April 6, 2015. Prior Sonnet completed a merger with publicly-held Chanticleer Holdings, Inc. (“Chanticleer”) on April 1, 2020. After the merger, Chanticleer changed its name to Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”). Sonnet is a clinical stage, oncology-focused biotechnology company with a proprietary platform for innovating biologic medicines of single- or bi-specific action. Known as F<sub>H</sub>AB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (“HSA”) for transport to target tissues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonnet’s lead proprietary asset, SON-1010, is a fully human version of Interleukin 12 (“IL-12”), covalently linked to the F<sub>H</sub>AB construct, for which Sonnet intends to pursue clinical development in solid tumor indications, including ovarian cancer, non-small cell lung cancer and head and neck cancer. In March 2022, the FDA cleared Sonnet’s Investigational New Drug (“IND”) application for SON-1010. This allowed the Company to initiate a U.S. clinical trial (SB101) in oncology patients with solid tumors during the second calendar quarter of 2022. In September 2021, the Company created a wholly-owned Australian subsidiary, SonnetBio Pty Ltd (“Subsidiary”), for the purpose of conducting certain clinical trials. Sonnet received approval and initiated an Australian clinical study (SB102) of SON-1010 in healthy volunteers during the third calendar quarter of 2022. Interim safety and tolerability data from the SB101 and SB102 studies were reported in April 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023, Sonnet announced a collaboration agreement with Roche for the clinical evaluation of SON-1010 with atezolizumab (Tecentriq®). The companies have entered into a Master Clinical Trial and Supply Agreement (“MCSA”), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (“PROC”) patient setting. Further, the companies will provide SON-1010 and atezolizumab, respectively, for use in the Phase 1b/Phase 2a combination safety, dose-escalation, and efficacy study (SB221). The SB221 study has been formally submitted for final approval in Australia and preparations are on track to initiate the study during the second calendar quarter of 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acquired the global development rights to its most advanced compound, SON-080, a fully human version of Interleukin 6 (“IL-6”), in April 2020 through its acquisition of the outstanding shares of Relief Therapeutics SA. Sonnet is advancing SON-080 in target indications of Chemotherapy-Induced Peripheral Neuropathy (“CIPN”) and Diabetic Peripheral Neuropathy (“DPN”). Sonnet received approval to initiate an ex-U.S. Phase 1b/2a study with SON-080 in CIPN. This study is on track to yield initial clinical safety data during the first half of calendar 2023. Pursuant to a license agreement the Company entered with New Life Therapeutics Pte, Ltd. (“New Life”) of Singapore in May 2021, Sonnet and New Life are jointly responsible for developing SON-080 in DPN. The objective will be to evaluate the data and potentially initiate a Phase 2 study in the second half of calendar 2023, once the CIPN safety data has been evaluated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SON-1210 (IL12-F<sub>H</sub>AB-IL15), Sonnet’s lead bi-specific construct, combines F<sub>H</sub>AB with fully human IL-12 and fully human Interleukin 15 (“IL-15”). This compound is being developed for solid tumor indications, including colorectal cancer. In February 2023, the Company announced the successful completion of two IND-enabling toxicology studies with SON-1210 in non-human primates. Sonnet remains on track to initiate the regulatory authorization process for SON-1210 in the first half of calendar 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SON-1410 (IL18-F<sub>H</sub>AB-IL12) is a bi-specific combination of Interleukins 18 (“IL-18”) and 12 (IL-12) for solid tumor cancers. Cell line development and process development are ongoing, with early experimental drug supply suitable for formulation and analytical method development activities, in addition to small quantities for use in early development proof-of-concept <i>in vitro</i> studies. Process development activities will continue through 2023, with the potential to generate a drug suitable for initial <i>in vivo</i> mice studies by the end of the 2023 calendar year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has completed sequence confirmation for SON-3015 (anti-IL6-F<sub>H</sub>AB-anti-TGFβ). Early stage bi-specific drug has been generated and is being stored for future use in <i>in vivo</i> mice studies. Sonnet has elected to place the SON-3015 development program on hold for expense reduction purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sonnet BioTherapeutics Holdings, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Unaudited Interim Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the ongoing cost-cutting evaluations, all antiviral development with SON-1010 has been suspended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred recurring losses and negative cash flows from operations since inception and expects to generate losses from operations for the foreseeable future, primarily due to research and development costs for its potential product candidates. The Company believes its cash of $<span id="xdx_904_eus-gaap--Cash_iI_pn5n6_c20230331_ztYHAa7Pvt74" title="Cash">11.4</span> million at March 31, 2023 will fund the Company’s projected operations into January <span style="background-color: white">2024</span>. Substantial additional financing will be needed by the Company to fund its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited interim consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company plans to secure additional capital in the future through equity or debt financings, partnerships, collaborations, or other sources to carry out the Company’s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company’s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company’s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company’s financial condition and future operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations since inception have consisted primarily of organizing the Company, securing financing, developing its technologies through performing research and development and conducting preclinical studies. The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash Cash	11400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zCCrQwZRAHye" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c. <span id="xdx_86A_zGo7ytGqcqKk">Use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the interim unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited interim consolidated financial statements include the accrual of research and development expenses. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from management’s estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zAblxjciBXRa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d. <span id="xdx_867_zw4Nxy3q8Rsc">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts from the prior period have been reclassified to conform with the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Refund Received Related To Revenue From Different Year Year Revenue Recognized RefundReceivedRelatedToRevenueFromDifferentYearYearRevenueRecognized	The cash refund is available to eligible companies with annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable period.
CY2023Q1	SONN	Cash Refund Expected To Be Received CashRefundExpectedToBeReceived	100000	usd
CY2022Q1	SONN	Cash Refund Expected To Be Received CashRefundExpectedToBeReceived	100000	usd
	SONN	Cash Refund Expected To Be Received CashRefundExpectedToBeReceived	300000	usd
	SONN	Cash Refund Expected To Be Received CashRefundExpectedToBeReceived	100000	usd
CY2023Q1	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	1100000	usd
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-14 reverse stock split
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32424490	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3766751	shares
CY2023Q1	SONN	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	1801489	usd
CY2022Q3	SONN	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	1218530	usd
CY2023Q1	SONN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	692477	usd
CY2022Q3	SONN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1593922	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	325927	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	378890	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	292389	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2630	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3112282	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3193972	usd
	us-gaap	Collaborative Arrangement Rights And Obligations CollaborativeArrangementRightsAndObligations	New Life is also obligated to pay a non-refundable deferred license fee of an additional $1.0 million at the time of the satisfaction of certain milestones, as well as potential additional milestone payments to the Company of up to $19.0 million subject to the achievement of certain development and commercialization milestones. In addition, during the Royalty Term (as defined below), New Life is obligated to pay the Company tiered double-digit royalties ranging from 12% to 30% based on annual net sales of Products in the Exclusive Territory. The “Royalty Term” means, on a Product-by-Product and a country-by-country basis in the Exclusive Territory, the period commencing on the date of the first commercial sale (subject to certain conditions) of such Product in such country in the Exclusive Territory and continuing until New Life ceases commercialization of such Product in the DIPN Field.
	SONN	Performanceobligation Performanceobligation	1000000.0	usd
CY2023Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	36445	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	100000	usd
CY2022Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	100000	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	200000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	2059	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	7549	shares
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	56998	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	148615	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	350891	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	682966	usd
CY2022Q3	SONN	Exercise Tax Rate On Corporate Stock Repurchases ExerciseTaxRateOnCorporateStockRepurchases	0.01	pure

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-016046-index-headers.html	Edgar Link	pending
0001493152-23-016046-index.html	Edgar Link	pending
0001493152-23-016046.txt	Edgar Link	pending
0001493152-23-016046-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sonn-20230331.xsd	Edgar Link	pending
sonn-20230331_cal.xml	Edgar Link	unprocessable
sonn-20230331_def.xml	Edgar Link	unprocessable
sonn-20230331_lab.xml	Edgar Link	unprocessable
sonn-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SONN
Sonnet Biotherapeutics Holdings Inc Stock $sonn

2023 Q2 Form 10-Q Financial Statement

#000149315223016046 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SONN Sonnet Biotherapeutics Holdings Inc Stock $sonn

2023 Q2 Form 10-Q Financial Statement

#000149315223016046 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SONN
Sonnet Biotherapeutics Holdings Inc Stock $sonn